DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162490

Pharmacoeconomic analysis of drugs used for peptic ulcer in India

Bhanu Prakash Kolasani, C. M. Divyashanthi

Abstract


Background: Acid peptic disorders are common medical problems in daily clinical practice leading to a significant economic burden on healthcare expenses. Due to lack of information on comparative drug prices and quality, it becomes difficult for physicians to prescribe the most economical treatment. So the present study was planned to analyse the price variations of various anti-ulcer drugs available in India.

Methods: The cost of a particular anti-ulcer drug being manufactured by different companies, in the same dose and dosage forms, was obtained from latest issue of ‘‘current index of medical specialties’’ January to April, 2016. The difference between the maximum and minimum prices of same drug was analysed and percentage variation in the prices was calculated.

Results: Overall, the prices of a total of 12 anti-ulcer drugs belonging to four different categories available in 38 different formulations were analysed.  Among the proton pump inhibitors, pantoprazole (40 mg; EC tablet) showed the maximum price variation of 500.75%. With regard to H2 blockers, ranitidine (50 mg; injection) showed the maximum price variation of 989.92%. The maximum price variation among various formulations of ulcer protective was seen with sucralfate (1000 mg; tablet) of 166.00% while misoprostol (200µg; tablet) was the only drug present in prostaglandin analogues and it showed a price variability of 14.33%.

Conclusions: The average percentage variations of different brands of the same anti-ulcer drugs in same dose and dosage form manufactured in India were very wide. The government and drug manufacturing companies must direct their efforts in reducing the cost of anti-ulcer drugs and thereby minimizing the economic burden on the patients.


Keywords


Cost analysis, Proton pump inhibitors, H2 blockers, Ulcer protective

Full Text:

PDF

References


Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65:264-81.

Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-11.

Cappell MS. Clinical presentation, diagnosis, and management of gastroesophageal reflux disease. Med Clin North Am. 2005;89:243-91.

Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25:180-6.

Rao KS, Nundy M, Dua AS. National commission on macroeconomics and health. financing and delivery of health care services in India. New Delhi: Ministry of Health and Family Welfare, Government of India, Delivery of Health Services in the Private Sector; 2005:89-104.

Sakthivel S. Access to essential drugs and medicines. In: Lal PG (Ed.) National Commission on Macroeconomics and Health. New Delhi: Ministry of Health; 2005:185-210.

Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci. 2013;2(1):63-9.

Indian Drug Review (IDR). 2014;21(4).

Adam T, Evans DB, Murray CJL. Cost effectiveness and resource allocation. 2003;1:3. Available at http://www.resource-allocation.com/content/1/1/3. Accessed on 11 August 2009.

Olkinuora M, Asp S, Juntunen J, Kauttu K, Strid L, Aarimaa M. Stress symptoms, burnout and suicidal thoughts in Finnish physicians. Soc Psychiatry Psychiatr Epidemiol. 2004;25(2):81-6.

Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol. 2006;3:80-9.

Tajima A, Koizumi K, Suzuki K, Higashi N, Takahashi M, Shimada T, et al. Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008;23:S237-S234.

Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009;20:171-3.

Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine: panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172-7.

Paunikar AP, Bhave KA. Cost analysis of oral antidepressant drugs available in India. Natl J Physiol Pharm Pharmacol. 2015;5(5):367-71.

Lofolm PW, Katzug BG. Rational prescribing and prescription writing. In: Katzug BG (Ed.) Basic and Clinical Pharmacology, 9th edn. New York: McGraw-Hill; 2012:1091-100.

Roy V, Gupta U, Agarwal K. Cost of medicines and their affordability in private pharmacies in Delhi (India). Indian J Med Res. 2012;136(5):827-35.

Levy-Neumand O, Carniaux F, Bonaz B, Durand A, Roblin X. Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications. Gastroenterol Clin Biol. 2007;31:78-83.

Kumar V, Gupta NV, Kumar KA. A comparison between old and latest systems in DPCO. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(2):19-20.

National List of Essential Medicines of India, 2015. Available at http://mohfw.nic.in/WriteReadData/l892s/7364497513National%20List%20of%20Essential%20Medicine,%202011.pdf. Accessed on 28 March 2015.

Creese A, Kotwani A, Kutzin J, Pillay A. Evaluating pharmaceuticals for health policy in low and middle income country settings. In: Freemantle N, Hill S, editors. Evaluating pharmaceuticals for health policy and reimbursement. Massachusetts, USA: Blackwell Publication; (in collaboration with WHO Geneva); 2004:227-43.

Mahal A, Karan A, Engelgau M. The economic implications of non-communicable disease for India. Washington, DC: World Bank; 2010. Available at http://www.environmentportal.in/files/NCDforIndia.pdf.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160:3.